Why the study?
Does pharmaceutical intervention affect the lipid profile in women with polycystic ovary syndrome?
Population
Women with polycystic ovary syndrome (PCOS)
Design
Review
Authors
Loading...
May warrant lipid consideration in PCOS care; leaves open need for RCTs on cardiovascular outcomes.
Does pharmaceutical intervention affect the lipid profile in women with polycystic ovary syndrome?
Dyslipidemia is a common cardiometabolic risk factor in PCOS that requires consideration during pharmaceutical treatment.
Diamanti‐Kandarakis et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: